Company intelligence / Profile preview

NeuroCytonix

Rockville, Maryland, United Statesneurocytonix.com ↗

Ownership: Private
Employees: ~39
Development stage: Phase 1

Overview

NeuroCytonix has completed a double-blind, placebo-controlled clinical trial of its non-invasive NeuroCytotron device/protocol in cerebral palsy patients with encouraging results. The company recently received regulatory approval to begin a pilot clinical study evaluating the same technology for autism spectrum disorder. Early case reports suggest improvements in communication and engagement among autistic children treated with the device. The company aims to expand its approach to additional neurological conditions such as stroke and neurodegenerative diseases.

Therapeutic areas: PsychiatryNeurology
Modalities: Non-invasive neuromodulation (magnetic fields and radiofrequency waves)Tissue engineering for neural regeneration
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

NeuroCytotron

Phase 1

Indications: Cerebral palsy, Autism

Beyond the preview

Go deeper on NeuroCytonix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroCytonix.

Explore the full profile